ITGAM and colitis: Indeed, administration of rIL‐22 ameliorated POM‐1‐dependent augmentation of colitis disease activity (Figure 3a), reversed the shortening of colon length (Figure 3b) and reduced the infiltration of CD11b+Ly‐6G+ neutrophils and CD11b+Ly‐6G− macrophages in the colon (Figure 3c).